PubMed Health⌕ Search

Biomedical subjects

A Larson

Publications and source records attributed to A Larson.

76 records · Page 5Linked to original sources
PubMedDate not supplied

Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.

Although H&H combination treatment (high active TIL and high sensitive drugs) as previously described to solid tumor patients is more efficient than single-agent treatments such as TIL adoptive immunotherapy, it has a short-term efficiency for the immune response to metastatic cancers. Currently, a new version of the combination of active and adoptive immune response was established. TILs, tumor vaccines and high sensitive drugs. The experimental results demonstrated that TILs from 49 cases (65%) were more than 1,000 expansion-fold and only 6 cases (24%) less than 500 fold. The peaks of TIL 3H-TdR cytotoxicity test from 35 of 64 TIL specimens were kept from 40 to 56 days. TIL phenotypes studied here indicated CD3 80 +/- 21%, CD4 37 +/- 21%, CD8 44 +/- 18% and HLA DR 69 +/- 24% after IL2 induction, in contrast, to CD3 20 +/- 12%, CD4 10 +/- 7%, CD8 11 +/- 3% and HLA DR 30 +/- 16% before induction. Thirty two of 75 cases were assayed using the chemosensitivity test. The distribution of positive rates for the chemosensitivity test were slightly different in different tumors regarding tissues in liver, lung, ovary, breast, and melanoma, 2 cases with melanoma all showed negative results. The results of a tumor vaccine using TNF-alpha gene transduction demonstrated that the expression of HLA Class I and HLA Class II were dramatically increased 87% and 43%. After implanting tumor cells via transduced TNF-alpha retroviral vector into 6-12 week old BALB/c nude mice, only one subject of nine nude mice had a tumor weight of 2.67 g, but the control group all displayed tumors with a weight of 3.24 +/- 0.56 g. Preliminarily clinical trials also showed that the new version was obviously a promising combination.

Animals↗
PubMedDate not supplied

Chronic hepatitis C: common questions, practical answers.

BACKGROUND: The hepatitis C virus (HCV) is the most common cause of chronic liver disease in the United States. Dramatic advances have been made recently in the treatment of this potentially life-threatening infection by using a combination interferon and ribavirin therapy. METHODS: The most common questions regarding chronic HCV infections that occur in the course of clinical practice of primary care physicians were elicited through e-mail and telephone interviews. To answer these questions, computerized literature searches of the MEDLINE database were performed and expert opinion was sought. RESULTS: For many patients with HCV who are treated with combination therapy, there is now a greater than 30% chance of achieving long-term normalization of transaminase levels and the loss of detectable viral load. Treatment is expensive, however, and can be difficult to tolerate. The effect of treatment on the risk of progression to liver failure and hepatocellular carcinoma is promising but has not yet been determined. CONCLUSIONS: Primary care physicians play an important role in the diagnosis and initial workup of patients with HCV. By understanding the correct use of HCV diagnostic testing and the risks and benefits of antiviral therapy, providers will be better equipped to screen and counsel their patients infected with HCV.

Alanine Transaminase↗